JP Morgan initiated coverage on Immunovant Sciences with a new price target
$IMVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan initiated coverage of Immunovant Sciences with a rating of Overweight and set a new price target of $51.00